Parallax Volatility Advisers’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-2,000
| Closed | -$156K | – | 1707 |
|
|
2025
Q3 | $156K | Buy |
+2,000
| New | +$156K | ﹤0.01% | 1392 |
|
|
2025
Q1 | – | Sell |
-60,000
| Closed | -$4.44M | – | 1733 |
|
|
2024
Q4 | $4.44M | Sell |
60,000
-130,000
| -68% | -$9.1M | 0.01% | 866 |
|
|
2024
Q3 | $12.5M | Buy |
190,000
+140,000
| +280% | +$10.2M | 0.02% | 466 |
|
|
2024
Q2 | $4.62M | Buy |
+50,000
| New | +$4.43M | 0.01% | 743 |
|
|
2023
Q4 | – | Sell |
-100
| Closed | -$6.93K | – | 2262 |
|
|
2023
Q3 | $6.93K | Hold |
100
| – | – | ﹤0.01% | 2133 |
|
|
2023
Q2 | $9.43K | Sell |
100
-63,800
| -100% | -$5.55M | ﹤0.01% | 2185 |
|
|
2023
Q1 | $5.29M | Buy |
63,900
+13,300
| +26% | +$1.05M | 0.01% | 835 |
|
|
2022
Q4 | $3.78M | Buy |
50,600
+49,000
| +3,063% | +$3.78M | 0.01% | 1137 |
|
|
2022
Q3 | $133K | Sell |
1,600
-1,600
| -50% | -$154K | ﹤0.01% | 2417 |
|
|
2022
Q2 | $305K | Sell |
3,200
-8,000
| -71% | -$828K | ﹤0.01% | 2085 |
|
|
2022
Q1 | $1.32M | Buy |
+11,200
| New | +$1.26M | ﹤0.01% | 1534 |
|
|
2020
Q4 | – | Sell |
-62,800
| Closed | -$5.01M | – | 2924 |
|
|
2020
Q3 | $5.01M | Sell |
62,800
-101,300
| -62% | -$7.9M | ﹤0.01% | 1314 |
|
|
2020
Q2 | $11.3M | Sell |
164,100
-6,000
| -4% | -$426K | 0.01% | 724 |
|
|
2020
Q1 | $10.7M | Buy |
170,100
+132,900
| +357% | +$9.58M | 0.01% | 575 |
|
|
2019
Q4 | $2.89M | Buy |
+37,200
| New | +$2.9M | ﹤0.01% | 1125 |
|
|
2019
Q2 | – | Sell |
-135,000
| Closed | -$8.61M | – | 2852 |
|
|
2019
Q1 | $8.61M | Buy |
135,000
+90,000
| +200% | +$5.14M | 0.01% | 523 |
|
|
2018
Q4 | $2.3M | Hold |
45,000
| – | – | ﹤0.01% | 1012 |
|
|
2018
Q3 | $2.61M | Buy |
+45,000
| New | +$2.2M | ﹤0.01% | 946 |
|
|
2018
Q2 | – | Sell |
-45,000
| Closed | -$2.09M | – | 2401 |
|
|
2018
Q1 | $2.09M | Buy |
+45,000
| New | +$1.95M | ﹤0.01% | 758 |
|
|
2017
Q3 | – | Sell |
-41,700
| Closed | -$1.64M | – | 2370 |
|
|
2017
Q2 | $1.64M | Buy |
+41,700
| New | +$1.52M | ﹤0.01% | 901 |
|
|
2017
Q1 | – | Sell |
-30,000
| Closed | -$937K | – | 3804 |
|
|
2016
Q4 | $937K | Buy |
+30,000
| New | +$972K | ﹤0.01% | 1250 |
|
|
2016
Q3 | – | Sell |
-90,000
| Closed | -$2.99M | – | 3110 |
|
|
2016
Q2 | $2.99M | Buy |
90,000
+45,000
| +100% | +$1.54M | 0.01% | 791 |
|
|
2016
Q1 | $1.32M | Buy |
+45,000
| New | +$1.24M | ﹤0.01% | 1072 |
|
Other funds holding EW
VCM
VPM
Parallax Volatility Advisers's EW Position: Q1 2025 in Review
Parallax Volatility Advisers sold out of Edwards Lifesciences (EW) in Q1 2025, closing a stake of 8 shares — an estimated $573 sold.
Parallax Volatility Advisers first reported a position in EW in Q4 2014 and held it in 17 quarters. The position peaked at $23.6M in Q1 2019. 1,205 funds tracked by Wall St. Rank hold EW as of Q1 2025.
- Parallax Volatility Advisers reported no remaining Edwards Lifesciences position as of Q1 2025 after selling out during the quarter.
- Parallax Volatility Advisers sold 8 Edwards Lifesciences shares in Q1 2025, an estimated $573.
- Parallax Volatility Advisers first reported a position in Edwards Lifesciences in Q4 2014 and held it in 17 quarters.
- Parallax Volatility Advisers's Edwards Lifesciences position peaked at $23.6M in Q1 2019.
- 1,205 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2025.
Based on Parallax Volatility Advisers's 13F filing for Q1 2025, filed 15 May 2025.